ArticleNeurobiology of aging2025
Biological age acceleration in Alzheimer's disease modulates relative cortical to medial temporal lobe neurodegeneration.
Article in Neurobiology of aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aging modulates amyloid clearance kinetics during anti-amyloid therapy: evidence from real-world serial amyloid PET.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Alzheimer's disease (AD) is highly associated with aging, typically presenting with amnestic, multi-domain cognitive impairment and greater medial temporal lobe (MTL) atrophy relative to cortex. However, approximately 15 % of AD cases present atypically, often at younger ages and with greater cortical involvement relative to MTL. This association between age and AD presentation is imperfect: some younger-onset cases are typical, amnestic presentations while some older-onset cases present less typically. We hypothesize that this discordance may be partially modulated by discordance between chronological age and biological age, defined epigenetically. Participants from the Alzheimer's Disease Neuroimaging Initiative with MRI and known amyloid status were selected (n = 1011, 44.4 % female, 75.33 ± 7.28 years) and classified as amyloid-negative, cognitively unimpaired (n = 329) or amyloid-positive, symptomatic individuals with mild cognitive impairment or dementia (n = 682). Biological age was estimated in individuals with DNA methylation (n = 448) using established epigenetic clocks. Biological age gap (BAG) was calculated to categorize individuals into "accelerated" (biological age > chronological age) or "decelerated" (biological age < chronological age) groups. We define the Cortico-Medial Temporal index (CoMeT), derived from MRI, to quantify age-adjusted relative differences between cortical and MTL structures. Lower CoMeT scores indicate relatively greater cortical involvement. BAG and CoMeT were significantly correlated (Pearson R=0.13, p = 0.023). Symptomatic individuals with decelerated BAG exhibited significantly lower CoMeT scores than individuals with accelerated BAG, with a large effect size, reflecting greater cortical involvement relative to MTL (Wilcoxon p = 0.023, rank-biserial correlation=-0.98). We conclude that biological aging modulates AD presentation beyond chronological age, providing novel insights into mechanisms underlying AD heterogeneity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.